Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Appl Physiol (1985) ; 114(3): 361-70, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23221955

RESUMEN

The terminals of vagal lung C fibers (VLCFs) express various types of pharmacological receptors that are important to the elicitation of airway reflexes and the development of airway hypersensitivity. We investigated the blockade of the reflex and afferent responses of VLCFs to intravenous injections of agonists using perivagal treatment with antagonists (PAT) targeting the transient receptor potential vanilloid 1, P2X, and 5-HT(3) receptors in anesthetized rats. Blockading these responses via perivagal capsaicin treatment (PCT), which blocks the neural conduction of C fibers, was also studied. We used capsaicin, α,ß-methylene-ATP, and phenylbiguanide as the agonists, and capsazepine, iso-pyridoxalphosphate-6-azophenyl-2',5'-disulfonate, and tropisetron as the antagonists of transient receptor potential vanilloid 1, P2X, and 5-HT(3) receptors, respectively. We found that each of the PATs abolished the VLCF-mediated reflex apnea evoked by the corresponding agonist, while having no effect on the response to other agonists. Perivagal vehicle treatment failed to produce any such blockade. These blockades had partially recovered at 3 h after removal of the PATs. In contrast, PCT abolished the reflex apneic response to all three agonists. Both PATs and PCT did not affect the myelinated afferent-mediated apneic response to lung inflation. Consistently, our electrophysiological studies revealed that each of the PATs prevented the VLCF responses to the corresponding agonist, but not to any other agonist. PCT inevitably prevented the VLCF responses to all three agonists. Thus these PATs selectively blocked the stimulatory action of corresponding agonists on the VLCF terminals via mechanisms that are distinct from those of PCT. PAT may become a novel intervention for studying the pharmacological modulation of VLCFs.


Asunto(s)
Fibras Nerviosas Amielínicas/efectos de los fármacos , Fibras Nerviosas Amielínicas/fisiología , Neuronas Aferentes/efectos de los fármacos , Neuronas Aferentes/fisiología , Reflejo/efectos de los fármacos , Nervio Vago/efectos de los fármacos , Nervio Vago/fisiología , Animales , Apnea/tratamiento farmacológico , Apnea/metabolismo , Apnea/fisiopatología , Presión Arterial/efectos de los fármacos , Presión Arterial/fisiología , Temperatura Corporal/efectos de los fármacos , Temperatura Corporal/fisiología , Capsaicina/metabolismo , Arteria Femoral/efectos de los fármacos , Arteria Femoral/fisiología , Vena Femoral/efectos de los fármacos , Vena Femoral/fisiología , Inyecciones Intravenosas , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Pulmón/fisiología , Masculino , Fibras Nerviosas Amielínicas/metabolismo , Neuronas Aferentes/metabolismo , Agonistas del Receptor Purinérgico P2/farmacología , Antagonistas del Receptor Purinérgico P2X/farmacología , Ratas , Ratas Sprague-Dawley , Receptores Purinérgicos P2X/metabolismo , Receptores de Serotonina 5-HT3/metabolismo , Reflejo/fisiología , Antagonistas del Receptor de Serotonina 5-HT3/farmacología , Canales Catiónicos TRPV/metabolismo , Nervio Vago/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA